XML 41 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
License and Collaboration Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May 30, 2016
Mar. 01, 2016
Sep. 16, 2014
Apr. 30, 2016
Mar. 31, 2016
Nov. 30, 2015
Aug. 31, 2015
Mar. 31, 2015
Jun. 30, 2014
Jun. 30, 2013
Feb. 29, 2012
Jun. 30, 2016
Dec. 31, 2013
Dec. 31, 2010
Dec. 31, 2009
Jun. 30, 2016
Dec. 31, 2013
Dec. 31, 2007
Jul. 31, 2016
Dec. 31, 2015
Jul. 31, 2015
Deferred Revenue Arrangement [Line Items]                                          
Potential future additional payments for development milestones                               $ 147,000,000          
Accounts receivable, net                       $ 27,777,000       27,777,000       $ 19,947,000  
Liability for refundable upfront payment                       12,500,000       12,500,000       $ 0  
ONZEALDTM (NKTR-102) [Member] | Turkey [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Percentage of royalty on net sales 15.00%                                        
AstraZeneca-ProStrakan [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Percentage of upfront payment, market access milestones, royalties and sales milestones   40.00%                                      
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Eligible milestone payments receivable upon achievement of regulatory and commercial milestones $ 60,000,000                                        
Milestone payments to be received upon first commercial sales 10,000,000                                        
Milestone payment to be received upon first commercial sale after final regulatory approval 25,000,000                                        
Milestone payments to be received upon first achievement of annual net sales target $ 25,000,000                                        
Accounts receivable, net                       20,000,000       20,000,000          
Liability for refundable upfront payment                       12,500,000       12,500,000          
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | European Territory Except Turkey [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Percentage of royalty on net sales 20.00%                                        
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | Upfront Payment Arrangement [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Upfront and milestone payments receivable under license agreement $ 20,000,000                                        
Non-refundable portion of upfront payment $ 7,500,000                                        
Revenue recognized from upfront payment                       3,300,000                  
Deferred revenue                       4,200,000       4,200,000          
AstraZeneca AB [Member] | United States [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Liability to AZ for DTC advertising payments               $ 10,000,000                         $ 5,000,000
Reduction of revenue               (10,000,000)                          
AstraZeneca AB [Member] | United States [Member] | Scenario, Forecast [Member] | Other Current Liabilities [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Liability to AZ for DTC advertising payments                                     $ 5,000,000    
AstraZeneca AB [Member] | MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119) [Member] | Upfront Payment Arrangement [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Received upfront and milestone payments                             $ 125,000,000            
AstraZeneca AB [Member] | Movantik Fixed-dose Combination Program [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Potential contingent payments based on development events                       75,000,000       75,000,000          
AstraZeneca AB [Member] | MOVANTIK [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Received upfront and milestone payments               $ 100,000,000                          
Percentage of post approval study costs to repay     33.00%                                    
Maximum potential reduction in royalties     $ 35,000,000                                    
AstraZeneca AB [Member] | MOVANTIK [Member] | United States [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Potential reduction in U.S. royalty rate for repayment     2.00%                                    
AstraZeneca AB [Member] | MOVANTIK [Member] | European Union [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Received upfront and milestone payments             $ 40,000,000                            
AstraZeneca AB [Member] | AstraZeneca-ProStrakan [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Deferred revenue                       0       0          
Received upfront and milestone payments       $ 28,000,000                                  
Upfront and milestone payments received by Our collaboration partner under sublicense arrangement   $ 70,000,000                                      
Percentage of upfront milestones royalty and sales milestone payments from sublicense agreement retained by our collaboration partner   60.00%                                      
Contingent payment recognized as revenue         $ 28,000,000                                
Baxalta Incorporated [Member] | ADYNOVATETM (Hemophilia) [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Deferred revenue                       0       0          
Development milestones achieved           $ 10,000,000                              
Baxalta Incorporated [Member] | ADYNOVATETM (Hemophilia) [Member] | European Union [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Potential future additional payments for development milestones                               10,000,000          
Roche [Member] | MIRCERA [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Consideration received for product delivered in 2013                         $ 18,600,000                
Roche [Member] | MIRCERA [Member] | Performance-based Milestone Payments [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Received upfront and milestone payments                     $ 22,000,000                    
Roche [Member] | MIRCERA [Member] | Upfront Payment Arrangement [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Received upfront and milestone payments                     $ 5,000,000                    
Roche [Member] | PEGASYS and MIRCERA [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Deferred revenue                       3,800,000       3,800,000          
Amgen, Inc. [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Deferred revenue                       21,700,000       21,700,000          
Received upfront and milestone payments                           $ 50,000,000              
Bayer Healthcare LLC [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Potential future additional payments for development milestones                               50,000,000          
Deferred revenue                       18,600,000       18,600,000          
Payment made to Bayer for cost of Phase 3 clinical trial                   $ 10,000,000                      
Bayer Healthcare LLC [Member] | Performance-based Milestone Payments [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Received upfront and milestone payments                                 $ 30,000,000        
Bayer Healthcare LLC [Member] | Upfront Payment Arrangement [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Received upfront and milestone payments                                   $ 40,000,000      
Ophthotech Corporation [Member] | Fovista [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Potential future additional payments for development milestones                               9,500,000          
Deferred revenue                       17,500,000       17,500,000          
Received upfront and milestone payments                 $ 19,800,000                        
Potential future development milestones upon acceptance for review of regulatory approval                       2,500,000       2,500,000          
Other [Member]                                          
Deferred Revenue Arrangement [Line Items]                                          
Potential future additional payments for development milestones                               45,500,000          
Deferred revenue                       $ 10,300,000       $ 10,300,000